Charles River Laboratories International, Inc.
CRL
$233.47
$3.581.56%
| 12/30/2023 | 09/30/2023 | 07/01/2023 | 04/01/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 1.01B | 1.03B | 1.06B | 1.03B | 1.10B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.01B | 1.03B | 1.06B | 1.03B | 1.10B |
| Cost of Revenue | 642.72M | 650.55M | 660.96M | 651.72M | 698.09M |
| Gross Profit | 370.75M | 376.07M | 398.98M | 377.65M | 401.76M |
| SG&A Expenses | 189.57M | 174.14M | 198.53M | 173.78M | 206.09M |
| Depreciation & Amortization | 34.02M | 34.23M | 34.27M | 34.92M | 35.43M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 866.32M | 858.92M | 893.77M | 860.42M | 939.61M |
| Operating Income | 147.16M | 167.70M | 166.17M | 168.96M | 160.23M |
| Income Before Tax | 208.71M | 112.87M | 128.66M | 131.04M | 244.92M |
| Income Tax Expenses | 19.75M | 24.85M | 29.22M | 27.09M | 55.82M |
| Earnings from Continuing Operations | 188.95M | 88.02M | 99.44M | 103.95M | 189.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.87M | -632.00K | -2.42M | -823.00K | -1.70M |
| Net Income | 187.08M | 87.39M | 97.02M | 103.13M | 187.41M |
| EBIT | 147.16M | 167.70M | 166.17M | 168.96M | 160.23M |
| EBITDA | 227.67M | 246.57M | 243.84M | 246.03M | 237.78M |
| EPS Basic | 3.65 | 1.70 | 1.89 | 2.02 | 3.68 |
| Normalized Basic EPS | 0.96 | 1.76 | 1.54 | 1.60 | 1.43 |
| EPS Diluted | 3.62 | 1.69 | 1.89 | 2.01 | 3.65 |
| Normalized Diluted EPS | 0.96 | 1.74 | 1.53 | 1.59 | 1.42 |
| Average Basic Shares Outstanding | 51.31M | 51.28M | 51.22M | 51.10M | 50.91M |
| Average Diluted Shares Outstanding | 51.62M | 51.61M | 51.47M | 51.43M | 51.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
